EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

JAK Inhibitors for Myelofibrosis: Strengths and Limitations

K Thaw, C N Harrison, P Sriskandarajah

Current Hematologic Malignancy Reports · 2024-12 · 19 (6) · 264-275

DOI: 10.1007/s11899-024-00744-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Hematologic Malignancy Reports, online erschienen am 14.10.2024. Verfasst von K Thaw und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Janus Kinase Inhibitors. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose of Review The landscape of myelofibrosis (MF) has changed since the discovery of the JAK2 V617F mutation and subsequent development of JAK inhibitors (JAKis). However, treatment with JAKis remain a challenge. In this review we critically analyze the strengths and limitations of currently available JAK inhibitors. Recent Findings In MF patients, JAK inhibitors have been associated with reduced symptom burden and spleen size, as well as improved survival. However, durability of response and development of treatment resistance remain an issue. Recently, there has been increased efforts to optimize treatment with the development of highly selective JAK inhibitors, as well as use of combination agents to counter disease resistance through targeting aberrant signaling pathways. Summary Treatment of MF patients with JAKi therapy can be challenging but the development of more potent and selective JAK inhibitors, as well as combination therapies, represent exciting treatment advances in this field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisJanus Kinase InhibitorsHumansJanus Kinase 2Signal TransductionTreatment Outcome

Stichwörter der Autor:innen

Blood cancerJAK-inhibitorsMyelofibrosisToxicity

Substanzen

Janus Kinase InhibitorsJanus Kinase 2

Autor:innen und Institutionen

  • Department of Haematology, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK.
  • Department of Haematology, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK. Claire.harrison@gstt.nhs.uk.

Zitieren

APA

Thaw, K., Harrison, C. N., & Sriskandarajah, P. (2024). JAK Inhibitors for Myelofibrosis: Strengths and Limitations. Current Hematologic Malignancy Reports, 19(6), 264-275. https://doi.org/10.1007/s11899-024-00744-9

Vancouver

Thaw K, Harrison CN, Sriskandarajah P. JAK Inhibitors for Myelofibrosis: Strengths and Limitations. Current Hematologic Malignancy Reports. 2024;19(6):264-275. doi:10.1007/s11899-024-00744-9

BibTeX
@article{Thaw2024,
  author = {Thaw, K and Harrison, C N and Sriskandarajah, P},
  title = {JAK Inhibitors for Myelofibrosis: Strengths and Limitations},
  journal = {Current Hematologic Malignancy Reports},
  year = {2024},
  volume = {19},
  number = {6},
  pages = {264--275},
  doi = {10.1007/s11899-024-00744-9}
}
Kostenlos starten →